Bevyxxa FDA Approval History
FDA Approved: Yes (First approved June 23, 2017)
Brand name: Bevyxxa
Generic name: betrixaban
Dosage form: Capsules
Company: Portola Pharmaceuticals, Inc.
Treatment for: Prevention of Venous Thromboembolism
Bevyxxa (betrixaban) is an oral, once-daily Factor Xa inhibitor anticoagulant for the extended-duration prophylaxis of venous thromboembolism (VTE) in at-risk adult patients hospitalized for an acute medical illness.
Development timeline for Bevyxxa
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.